Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2022-10-25 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1938 characters) and contains the header 'RNS Number : 0429E' and mentions 'RNS, the news service of the London Stock Exchange'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, immediate operational announcement. This type of short, time-sensitive regulatory update that doesn't fit into the major financial reporting categories (like 10-K, ER, IR) is best classified as a general Regulatory Filing (RNS), as it is explicitly distributed via the RNS system.
2022-10-25 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1921 characters) and contains the header 'RNS Number' and explicitly mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content itself is a brief announcement regarding a 'Price Monitoring Extension' for a security, which is a specific operational update related to trading rather than a comprehensive financial report (like 10-K or IR) or a standard corporate action (like DIV or ER). Since it is a general regulatory announcement disseminated via the RNS system that doesn't fit into the more specific categories (like DIRS, DIV, ER, etc.), the most appropriate classification is the general regulatory filing fallback category.
2022-10-25 English
Signs Commercial License Agreement with Genmab
M&A Activity Classification · 99% confidence The document begins with an 'RNS Number' and is dated October 25, 2022. It announces a significant corporate event: 'Scancell signs Commercial License Agreement with Genmab'. This type of announcement, detailing a major business transaction (licensing deal) and providing financial terms (upfront payment, milestones, royalties), is a standard regulatory disclosure. Since it is not a full financial report (10-K, IR), an earnings release (ER), a proxy statement (DEF 14A), or a management discussion (MDA), it falls under the category of general regulatory announcements. The presence of the RNS header and footer strongly suggests it is a filing made via the Regulatory News Service. While it contains business information, it is primarily a regulatory disclosure of a material event, making RNS the most appropriate general category if a more specific one like M&A (TAR) doesn't perfectly fit (this is a licensing deal, not a merger/takeover). Given the options, RNS serves as the best fit for a general, material regulatory announcement disseminated through the LSE's service.
2022-10-25 English
Change of Nominated Adviser
Regulatory Filings Classification · 98% confidence The document is very short (3627 characters) and begins with 'RNS Number : 7159C' and ends with standard RNS disclaimers. The core content announces a 'Change of Nominated Adviser' (Stifel Nicolaus Europe Limited appointed). This type of announcement, which is a specific corporate action update distributed via the RNS system but does not fit into the defined categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), is best classified as a general regulatory announcement or miscellaneous filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback category for non-standard, mandatory regulatory news releases that don't fit elsewhere.
2022-10-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled with 'RNS Number' and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which falls under regulatory disclosure requirements. The presence of 'RNS' branding and the nature of the content (reporting changes in voting rights percentage crossing a threshold) strongly indicate a regulatory filing related to share ownership notification. This aligns best with the 'Major Shareholding Notification' category (MRQ). Although it is an RNS announcement, the core content is the specific major holding notification, making MRQ more precise than the general RNS fallback.
2022-09-28 English
Preclinical data at the EuroMAbNet Annual Meeting
Earnings Release Classification · 99% confidence The document is identified by the RNS Number header and the presence of 'RNS Number : 3799A' and the closing statement 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates a regulatory announcement made via the London Stock Exchange's Regulatory News Service (RNS). The content describes Scancell Holdings Plc presenting preclinical data at a scientific meeting (EuroMAbNet 12th Annual Meeting) regarding its proprietary antibody platforms (GlyMab® and AvidiMab®). This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific operational/scientific update disseminated through the regulatory news channel. Since the document is a specific announcement disseminated via RNS, and it doesn't fit perfectly into categories like DIV, DIRS, or MANG, the most appropriate classification is the general regulatory announcement category, RNS, as it is the primary mechanism of dissemination described. FY 2022
2022-09-23 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.